The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Dec. 14, 2021

Filed:

Jan. 27, 2020
Applicant:

Cardurion Pharmaceuticals, Llc, Boston, MA (US);

Inventors:

Nobuyuki Matsunaga, Kanagawa, JP;

Takashi Nakahata, Kanagawa, JP;

Yuta Tanaka, Kanagawa, JP;

Hiroki Takahagi, Kanagawa, JP;

Yasufumi Miyamoto, Kanagawa, JP;

Rei Okamoto, Kanagawa, JP;

Takeshi Yoshikawa, Kanagawa, JP;

Yoshito Terao, Kanagawa, JP;

Takafumi Yukawa, Kanagawa, JP;

Keiko Kakegawa, Kanagawa, JP;

Yoichi Nishikawa, Kanagawa, JP;

Terufumi Takagi, Kanagawa, JP;

Masashi Takahashi, Kanagawa, JP;

Mallareddy Komandla, San Diego, CA (US);

Lily Kwok, San Diego, CA (US);

Joanne Miura, San Diego, CA (US);

Mark Sabat, San Diego, CA (US);

Nicholas Scorah, San Diego, CA (US);

Paul Tanis, San Diego, CA (US);

John Tyhonas, San Diego, CA (US);

Phong H. Vu, San Diego, CA (US);

Haixia Wang, San Diego, CA (US);

Xiaolun Wang, San Diego, CA (US);

Junya Shirai, Kanagawa, JP;

Tomohiro Okawa, Kanagawa, JP;

Zenyu Shiokawa, Kanagawa, JP;

Akito Shibuya, Kanagawa, JP;

Assignee:

Cardurion Pharmaceuticals, LLC, Cambridge, MA (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C07C 211/39 (2006.01); A61K 31/506 (2006.01); A61P 9/06 (2006.01); A61K 31/5377 (2006.01);
U.S. Cl.
CPC ...
A61K 31/506 (2013.01); A61K 31/5377 (2013.01); A61P 9/06 (2018.01);
Abstract

The present invention provides a compound having a CaMKII inhibitory action, which is expected to be useful as an agent for the prophylaxis or treatment of cardiac diseases (particularly catecholaminergic polymorphic ventricular tachycardia, postoperative atrial fibrillation, heart failure, fatal arrhythmia) and the like. The present invention relates to a compound represented by the formula (I): wherein each symbol is as defined in the specification,or a salt thereof.


Find Patent Forward Citations

Loading…